Professor of Medicine, Mayo Medical School
Hematology
Dr. Stephen M. Ansell, MD
|
|
Give Review
Stephen M. Ansell, MD works in the field of Hematology. He received 1 awards: "Regional Top Doctor". Stephen M. Ansell is a published physician. He published 100 publications, including: 'Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes.' He is registered with Medicare.
Publications
- Targeting the PD-1 pathway in patients with relapsed classic Hodgkin Lymphoma following allogeneic stem cell transplant is safe and effective.
- Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma.
- Large B-cell transformation in nodular lymphocyte predominant Hodgkin Lymphoma: forty-year experience from a single institution.
- A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with Peripheral...
- Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.
- Treatment of HIV/AIDS associated Cancers with immunotherapy targeting PD-1/PD-L1 instead of chemotherapy.
- Adult Systemic Anaplastic Large Cell Lymphoma: Recommendations for Diagnosis and Management.
- Nivolumab for the treatment of classical Hodgkin Lymphoma after failure of autologous stem cell transplant and Brentuximab.
- Personalized risk prediction for event-free survival at 24 months in patients with diffuse large b-cell Lymphoma.
- T-cell-mediated antitumor immunity in B-cell non-Hodgkin Lymphoma: activation, suppression and exhaustion.
- Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour Cells.
- Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell Lymphoma relapsing after rituximab, cycloph...
- Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin Lymphoma.
- Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin Lymphoma.
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma.
- Elevated serum levels of IL-2R, IL-1RA and CXCL9 are associated with a poor prognosis in follicular Lymphoma.
- Expression of the Chemokine Receptor Gene, CCR8, is Associated With DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma.
- Waldenström Macroglobulinemia and autoimmunity: what's the connection?
- Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell Lymphoma.
- Medical History, Lifestyle, Family History, and Occupational Risk Factors for Peripheral T-Cell Lymphomas: The InterLymph Non-Hodgkin Lymphoma Subtypes Project.
- Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin Lymphoma or metastatic renal cell carcinoma.
- Infused AutoGraft Lymphocyte to Monocyte Ratio and Survival in Diffuse Large B-Cell Lymphoma.
- ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous Disease with widely disparate clinical outcomes.
- Pattern of CD14+ Follicular Dendritic Cells and PD1+ T Cells Independently Predicts Time to Transformation in Follicular Lymphoma.
- MR elastography derived shear stiffness-a new imaging biomarker for the assessment of early tumor response to chemotherapy.
- Accuracy of self-reported tobacco use status among hematopoietic SCT patients.
- Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outc...
- Follicular Lymphoma: watch and wait is watch and worry.
- Induction Therapy for Advanced-stage Hodgkin Lymphoma: Late Intensification (ABVD Chemotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Transplant O...
- B-cell activating factor-receptor specific activation of tumor necrosis factor receptor associated factor 6 and the phosphatidyl inositol 3-kinase pathway in Lymphoma ...
- TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's Lymphoma.
- GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features.
- Constitutive activation of STAT5A and STAT5B regulates IgM secretion in Waldenstrom's Macroglobulinemia.
- Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma.
- CD4(+)CD25(+)FOXP3(+) malignant T cells in Sézary Syndrome are not necessarily functional regulatory T cells.
- Cytokine gene polymorphisms and progression-free survival in classical Hodgkin Lymphoma by EBV status: Results from two independent cohorts.
- Incidence of Supraventricular Arrhythmias during Autologous Peripheral Blood Stem Cell Transplantation.
- Genetic Factors and Pathogenesis of Waldenström's Macroglobulinemia.
- Malignant B cells at the helm in follicular Lymphoma.
- Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Researc...
- CXCR5 polymorphisms in non-Hodgkin Lymphoma risk and prognosis.
- Waldenström macroglobulinaemia: the key questions.
- Patients with immunoglobulin light chain amyloidosis undergoing autologous stem Cell transplantation have superior outcomes compared with patients with multiple myelom...
- Management of newly diagnosed symptomatic multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.
- A phase i trial of immunostimulatory CpG 7909 oligodeoxynucleotide and (90) yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-hodgkin Lymphoma.
- Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenström Macroglobulinemia 1.
- Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem Cell mobilization.
- The ubiquitin hydrolase UCH-L1 destabilizes mTOR complex 1 by antagonizing DDB1-CUL4 mediated ubiquitination of raptor.
- Hodgkin Lymphoma: 2012 update on diagnosis, risk-stratification, and management.
- The tumor microenvironment in follicular Lymphoma.
- Beyond targeting malignant B Cells.
- Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell Lymphoma.
- Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict Disease relapse and prognosis in diffuse large B-cell lymphoma patients.
- Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin Lymphoma.
- The Absolute Monocyte Count is Associated with Overall Survival in Patients Newly Diagnosed with Follicular Lymphoma.
- Innate Immune B cells gone bad.
- Annual clinical updates in hematological malignancies: A continuing medical education series. Hodgkin Lymphoma: 2011 update on diagnosis, risk-stratification, and mana...
- Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom's Macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity.
- Bone marrow stromal cells protect Lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance.
- Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory Lymphomas.
- Soluble IL-2R{alpha} facilitates IL-2-mediated Immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma.
- Identifying Patients With Follicular Lymphoma Who Are Likely to Benefit From an Idiotype Vaccine.
- Establishment and characterization of a novel Waldenstrom Macroglobulinemia cell line, MWCL-1.
- Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell Lymphoma.
- Specificity of IRF4 translocations for primary cutaneous anaplastic large cell Lymphoma: a multicenter study of 204 skin biopsies.
- GLI2 mediates cytokine crosstalk in the tumor microenvironment.
- Programmed death 1 is expressed in cutaneous infiltrates of mycosis fungoides and Sézary Syndrome.
- Novel therapeutic agents for B-cell Lymphoma: developing rational combinations.
- Jak/Stat Pathway in Waldenström's Macroglobulinemia.
- Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell Lymphomas by massively parallel genomic sequencing.
- Design and validity of a clinic-based case-control study on the molecular epidemiology of Lymphoma.
- A BAFF-R mutation associated with non-Hodgkin Lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling.
- Germline variation in apoptosis pathway genes and risk of non-Hodgkin's Lymphoma.
- Vitamin D insufficiency and prognosis in non-Hodgkin's Lymphoma.
- Diagnosis and management of Waldenström Macroglobulinemia: Mayo stratification of Macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
- A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem Cell conditioning regimen in patients with multiple myeloma.
- A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin Lymphoma.
- Comparison of error rates in single-arm versus randomized phase II Cancer clinical trials.
- Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom Macroglobulinemia.
- New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem Cell transplantation in patient...
- Statin use and prognosis in patients with diffuse large B-cell Lymphoma and follicular Lymphoma in the rituximab era.
- Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin Lymphoma.
- Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell Lymphoma by inhibiting Akt signaling through mTORC2.
- Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-Cell ratio predicts a clinical outcome of human colon carcinoma.
- Monocytes promote tumor Cell survival in T-Cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic Cells.
- B7-H1 (PD-L1, CD274) suppresses Host immunity in T-cell lymphoproliferative disorders.
- Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's Lymphoma.
- A proliferation-inducing ligand mediates follicular Lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian ta...
- Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin Lymphoma.
- Cytokines in the microenvironment of Waldenström's Macroglobulinemia.
- Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin Lymphoma.
- Wnt-erizing mantle cell Lymphoma.
- A role for IFN-lambda1 in multiple myeloma B Cell growth.
- Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's Lymphoma.
- Autologous stem Cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisc...
- Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituxima...
- Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.
- Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin Lymphoma: a prospective study.
- Genetically predicted longer telomere length is associated with increased risk of B-cell Lymphoma subtypes.
Schools
University of Pretoria Faculty of Medicine
Coronation Hospital
Mayo Grad School Med
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
Mayo School of Graduate Medical Education -
University of Pretoria Faculty of Medicine
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1558335935 | |
| NPPES Provider LastName | ANSELL | |
| NPPES Provider FirstName | STEPHEN | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Hematology | |
| Total Claim Count | 130.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1558335935 |
| Last Name Of The Provider | ANSELL |
| First Name Of The Provider | STEPHEN |
| View All |
Similar Doctors
|
|
Dr. Mark R. Litzow, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. C Christopher Hook, MD |
|
|
Dr. Joseph P. Colgan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Animesh D. Pardanani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Prashant Kapoor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Curtis A. Hanson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Svetomir N. Markovic, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Clive S. Zent, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven I. Robinson, MD |
|
|
Dr. David J. Inwards, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jessemy D. Neiger, MD |
|
|
Dr. Brian J. Davis, MD |
|
|
Dr. Wei Ding, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jessica L. Geiger, MD |
|
|
Dr. Ivy A. Petersen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Larry R. Past, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nanna H. Sulai, MD |